NewsMarkets

Health

FDA Rejects Lung Cancer Drug Ivonescimab From Summit Therapeutics And Akeso

The US regulator declined approval for the treatment, marking a setback for the biotech firms behind the therapy.

3 publishers · 3 articles · first seen 15 Nov 2026 · updated 4h ago

Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made

First reported by STAT, 2h 01m ahead of the next publisher · who breaks stories first

The story so far

3 publishers have covered this in 3 articles since 15 Nov 2026. STAT published first, on 15 November at 15:05 UTC; News Feed followed 2h 02m later. The most recent article, from The New York Times, appeared on 15 November at 20:33 UTC.

Outlets reporting it: News Feed (major outlet), The New York Times (major outlet), STAT.

No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.

Sources

Every article we clustered into this story. Headlines link to the publisher.

  1. F.D.A. Rejects Closely Watched Lung Cancer Drug From China The New York Times ·
  2. FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector News Feed ·
  3. STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics STAT

In this story

  • FDA
  • Summit Therapeutics
  • Akeso
Embed this story

Paste this into any web page to show the live odds, with a link back here.